SELLAS Life Sciences just sent its stock soaring 17% after announcing it's close to the final analysis of its late-stage leukemia drug trial. Their GPS therapy, aimed at keeping aggressive blood cancer in remission, is showing promising results—so much so that retail investors are calling the current price “absurd” and demanding double digits. With survival times looking better than expected, all eyes are on the final results. Could this be a game-changer for cancer treatment and investors? #Health #BodyHealth #stocks